Sectors
AGEN
Agenus Inc.
3.24
1 x 3.21
2 x 4.10
bid
ask
-
0.01
0.31%
2 @ 04:10 PM
3.30 +0.06 (1.85%)
| Ytd | 3.18% | |
| 1y | -37.45% |
3.19
day range
3.35
1.38
52 week range
19.69
| Open | 3.25 | Prev Close | 3.25 | Low | 3.19 | High | 3.35 | Mkt Cap | 145.00M |
| Vol | 653.77K | Avg Vol | 857.47K | EPS | 1.59 | P/E | 175.00 | Forward P/E | -0.28 |
| Beta | 1.55 | Short Ratio | 4.16 | Inst. Own | 37.10% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 3.36 | 200-d Avg | 3.64 | 1yr Est | 8.00 |
AGEN News
benzinga.com
Agenus Presents 3-Yr Landmark Phase 1b Data From Fully Enrolled C-800-01 Cohort Evaluating Botensili
Fully enrolled 123-patient Phase 1b cohort demonstrated 21.2-month median overall survival, 33% thre
businesswire.com
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metas
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-onc
benzinga.com
Agenus To Present 3-Yr Survival Data From Phase 1b C-800-01 Study Of Botensilimab Plus Balstilimab I
Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b studyAgenus